KKRC
IMPL

Kohlberg Kravis Roberts & Co’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Kohlberg Kravis Roberts & Co’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,135,971
Closed -$1.78M – 74
2023
Q3 		$1.78M Hold
4,135,971
– – 0.06% 49
2023
Q2 		$5.25M Hold
4,135,971
– – 0.16% 36
2023
Q1 		$5.79M Hold
4,135,971
– – 0.17% 34
2022
Q4 		$15.5M Hold
4,135,971
– – 0.52% 23
2022
Q3 		$20.1M Hold
4,135,971
– – 0.4% 21
2022
Q2 		$38.5M Hold
4,135,971
– – 0.51% 16
2022
Q1 		$26.3M Hold
4,135,971
– – 0.24% 24
2021
Q4 		$35.7M Hold
4,135,971
– – 0.2% 19
2021
Q3 		$50.4M Buy
4,135,971
+333,332
+9% +$4.84M 0.25% 18
2021
Q2 		$33.7M Buy
+3,802,639
New +$45.4M 0.14% 27

Other funds holding IMPL

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

Kohlberg Kravis Roberts & Co's IMPL Position: Q4 2023 in Review

Kohlberg Kravis Roberts & Co sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 4,135,971 shares — an estimated $1.78M sold.

Kohlberg Kravis Roberts & Co first reported a position in IMPL in Q2 2021 and held it in 10 quarters. The position peaked at $50.4M in Q3 2021. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

  • Kohlberg Kravis Roberts & Co reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Kohlberg Kravis Roberts & Co sold 4,135,971 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $1.78M.
  • Kohlberg Kravis Roberts & Co first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and held it in 10 quarters.
  • Kohlberg Kravis Roberts & Co's Impel Pharmaceuticals Inc. Common Stock position peaked at $50.4M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on Kohlberg Kravis Roberts & Co's 13F filing for Q4 2023, filed 14 Feb 2024.